Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 172

The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.

Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer?

Grove, Carolyn S., Vassiliou, George S.·2014·Disease Models & Mechanisms
DOI 10.1242/dmm.015974PMC PMC4107323
Open this paper in CoChat — free account

Abstract

Acute myeloid leukaemia (AML) is an uncontrolled clonal proliferation of abnormal myeloid progenitor cells in the bone marrow and blood. Advances in cancer genomics have revealed the spectrum of somatic mutations that give rise to human AML and drawn our attention to its molecular evolution and clonal architecture. It is now evident that most AML genomes harbour small numbers of mutations, which are acquired in a stepwise manner. This characteristic, combined with our ability to identify mutations in individual leukaemic cells and our detailed understanding of normal human and murine haematopoiesis, makes AML an excellent model for understanding the principles of cancer evolution. Furthermore, a better understanding of how AML evolves can help us devise strategies to improve the therapy and prognosis of AML patients. Here, we draw from recent advances in genomics, clinical studies and experimental models to describe the current knowledge of the clonal evolution of AML and its implications for the biology and treatment of leukaemias and other cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1242/dmm.015974

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Mutation burden and cancer incidence. (A) Comparison of the mean number of non-coding mutations per genome in tumours of different tissues (raw data from Lawrence et al., 2013). Error bars show the standard error of the mean. (B) UK annual incidence of various malignancies [Cancer Registry Statistics, 2011; (www.ons.gov.uk) and the Cancer Research UK website (www.cancerresearchuk.org/cancer-info/cancerstats/)]. An asterisk (*) signifies that the incidence data refer to the tissue of origin, rather than the specific cancer subtype shown in A (e.g. lung cancer rather than lung squamous cell or adenocarcinoma). CLL, chronic lymphocytic leukaemia; DLBCL, diffuse large B-cell lymphoma.
Fig. 1. Mutation burden and cancer incidence. (A) Comparison of the mean number of non-coding mutations per genome in tumours of different tissues (raw data from Lawrence et al., 2013). Error bars show the standard error of the mean. (B) UK annual incidence of various malignancies [Cancer Registry Statistics, 2011; (www.ons.gov.uk) and the Cancer Research UK website (www.cancerresearchuk.org/cancer-info/cancerstats/)]. An asterisk (*) signifies that the incidence data refer to the tissue of origin, rather than the specific cancer subtype shown in A (e.g. lung cancer rather than lung squamous cell or adenocarcinoma). CLL, chronic lymphocytic leukaemia; DLBCL, diffuse large B-cell lymphoma.CC BY · PubMed Central
Fig. 2. Recurrent mutation groups in de novo AML. Genes recurrently mutated in AML belong to distinct functional groups or pathways. The most prominent functional groups and genes associated with these are listed. The proportion of AMLs with mutations affecting each of these groups is displayed (data obtained from The Cancer Genome Atlas Research Network, 2013).
Fig. 2. Recurrent mutation groups in de novo AML. Genes recurrently mutated in AML belong to distinct functional groups or pathways. The most prominent functional groups and genes associated with these are listed. The proportion of AMLs with mutations affecting each of these groups is displayed (data obtained from The Cancer Genome Atlas Research Network, 2013).CC BY · PubMed Central
Fig. 3. Linear and branching clonal evolution. (A) Linear evolution. Sequential dominant clones (clonal sweep) result in a linear architecture with stepwise accumulation of driver mutations. The final tumour carries all mutations arising during the evolutionary history and overwhelms earlier clones carrying only some of the mutations. (B) Branching evolution. The final leukaemia might be dominated by a single clone, but clones arising through divergent mutational pathways are also evident. Small subclones might fall below the limit of detection, in which case the complexity of branching is underestimated. Smaller fitness effects of mutations and faster acquisition favour branching versus linear evolution. Numerals indicate the number of mutations in cells. Cells carrying identical mutations are represented in the same colour.
Fig. 3. Linear and branching clonal evolution. (A) Linear evolution. Sequential dominant clones (clonal sweep) result in a linear architecture with stepwise accumulation of driver mutations. The final tumour carries all mutations arising during the evolutionary history and overwhelms earlier clones carrying only some of the mutations. (B) Branching evolution. The final leukaemia might be dominated by a single clone, but clones arising through divergent mutational pathways are also evident. Small subclones might fall below the limit of detection, in which case the complexity of branching is underestimated. Smaller fitness effects of mutations and faster acquisition favour branching versus linear evolution. Numerals indicate the number of mutations in cells. Cells carrying identical mutations are represented in the same colour.CC BY · PubMed Central
Fig. 4. Common mutations in de novo and secondary AML. A number of clonal blood disorders with a myeloid phenotype are represented. Each of these disorders is characterised by recurrent mutations in specific genes, some of which are shared between several different phenotypes (e.g. TET2). All of these disorders can transform to secondary AML upon acquisition of additional somatic mutations. When AML arises in the absence of an antecedent clonal blood disorder, it is known as primary AML. aCML, atypical CML; CML, chronic myeloid leukaemia; ET, essential thrombocythaemia; IMF, idiopathic myelofibrosis; PV, polycythaemia vera; SM, systemic mastocytosis.
Fig. 4. Common mutations in de novo and secondary AML. A number of clonal blood disorders with a myeloid phenotype are represented. Each of these disorders is characterised by recurrent mutations in specific genes, some of which are shared between several different phenotypes (e.g. TET2). All of these disorders can transform to secondary AML upon acquisition of additional somatic mutations. When AML arises in the absence of an antecedent clonal blood disorder, it is known as primary AML. aCML, atypical CML; CML, chronic myeloid leukaemia; ET, essential thrombocythaemia; IMF, idiopathic myelofibrosis; PV, polycythaemia vera; SM, systemic mastocytosis.CC BY · PubMed Central
Fig. 5. Order of acquisition: constraint or opportunity? In many cancers, including AML, specific driver mutations are usually acquired early in the process of clonal evolution, whereas others are acquired late. Here we use the simplified example of two mutations that represent the only two driver events in AML. During the evolution of AML, mutation X (red square) is recurrently acquired first and mutation Y (blue oval) second. This pattern could be due to a strict requirement for a specific order in which mutations are acquired (constraint, panel A) or could simply reflect the statistical likelihood that mutations are acquired in this order (opportunity, panel B). We speculate that the key variables behind the concept of ‘opportunity’ are the number and longevity of cells susceptible to transformation (clonal size, represented here by the number of cells that inherit the mutation) and the speed with which additional mutations are acquired (mutagenesis rate). In panel Bi, mutation X leads to a marked clonal expansion in the progeny of the leukaemia-initiating cell (LIC). In turn, this increases the likelihood of a cell subsequently acquiring mutation Y and the development of leukaemia (solid arrow). Nevertheless, the development of leukaemia is not inevitable (dashed arrow). In panel Bii, mutation Y is acquired first in the putative LIC and does not facilitate the generation of progeny susceptible to transformation, such that the subsequent acquisition of mutation X is unlikely (solid arrow), but not impossible (dashed arrow). In panel Biii, mutation X has a neutral effect on the generation of LIC progeny, but causes accelerated mutagenesis and thus makes the likelihood of subsequent acquisition of mutation Y higher. In panel Biv, mutation Y is acquired first and here it has a neutral effect on initial LIC clonal size, but does lead to subsequent cell loss (e.g. by accelerating senescence), therefore markedly reducing the opportunity for acquiring additional mutations. Again, this eventuality, although unlikely, is not impossible. Finally, in panel Bv, mutation X leads to both clonal expansion and accelerated mutagenesis, making the development of leukaemia very likely or even inevitable. By the same token, a mutation with the opposite effects (i.e. no LIC clonal expansion or enhanced cell loss, and low mutagenesis rate) would make leukaemia very unlikely or impossible.
Fig. 5. Order of acquisition: constraint or opportunity? In many cancers, including AML, specific driver mutations are usually acquired early in the process of clonal evolution, whereas others are acquired late. Here we use the simplified example of two mutations that represent the only two driver events in AML. During the evolution of AML, mutation X (red square) is recurrently acquired first and mutation Y (blue oval) second. This pattern could be due to a strict requirement for a specific order in which mutations are acquired (constraint, panel A) or could simply reflect the statistical likelihood that mutations are acquired in this order (opportunity, panel B). We speculate that the key variables behind the concept of ‘opportunity’ are the number and longevity of cells susceptible to transformation (clonal size, represented here by the number of cells that inherit the mutation) and the speed with which additional mutations are acquired (mutagenesis rate). In panel Bi, mutation X leads to a marked clonal expansion in the progeny of the leukaemia-initiating cell (LIC). In turn, this increases the likelihood of a cell subsequently acquiring mutation Y and the development of leukaemia (solid arrow). Nevertheless, the development of leukaemia is not inevitable (dashed arrow). In panel Bii, mutation Y is acquired first in the putative LIC and does not facilitate the generation of progeny susceptible to transformation, such that the subsequent acquisition of mutation X is unlikely (solid arrow), but not impossible (dashed arrow). In panel Biii, mutation X has a neutral effect on the generation of LIC progeny, but causes accelerated mutagenesis and thus makes the likelihood of subsequent acquisition of mutation Y higher. In panel Biv, mutation Y is acquired first and here it has a neutral effect on initial LIC clonal size, but does lead to subsequent cell loss (e.g. by accelerating senescence), therefore markedly reducing the opportunity for acquiring additional mutations. Again, this eventuality, although unlikely, is not impossible. Finally, in panel Bv, mutation X leads to both clonal expansion and accelerated mutagenesis, making the development of leukaemia very likely or even inevitable. By the same token, a mutation with the opposite effects (i.e. no LIC clonal expansion or enhanced cell loss, and low mutagenesis rate) would make leukaemia very unlikely or impossible.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 94 references

Cited by

Metadata

Authors
Grove, C. S., & Vassiliou, G. S.
Affiliations
Haematological Cancer Genetics, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
Venue
Disease Models & Mechanisms
Publisher
The Company of Biologists
Published
2014-08-01
Volume
7
Issue
8
Pages
941-951
ISSN
  • 1754-8411
  • 1754-8403
DOI
10.1242/dmm.015974
PMC
PMC4107323
Cited by
172
References
94
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.